Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study

References

• Awad AG, Voruganti LN. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 2000; 26: 557–64
   PubMed Web of Science ®Google Scholar
• Hellewell JSE. Patients' subjective experiences of antipsychotics. Clinical relevance. CNS Drugs 2002; 16: 457–71
   PubMed Web of Science ®Google Scholar
• Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–28
   PubMed Web of Science ®Google Scholar
• Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11(Suppl 4)S397–403
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28(Suppl 1)9–26
   PubMed Web of Science ®Google Scholar
• Awad AG, Hogan TP, Voruganti LNP, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10(Suppl 3)123–32
   PubMed Web of Science ®Google Scholar
• Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001; 11(Suppl 4)S391–S6
   Web of Science ®Google Scholar
• Altamura AC, Bobes J, Cunningham Owens D, et al. Schizophrenia: diagnosis and continuing treatment. Principles of practice in the contemporary treatment of schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 1–12
   PubMed Web of Science ®Google Scholar
• Hellewell JSE, Gerlach J. Opportunities and challenges presented by the new generation antipsychotics. Int J Psychiatry Clin Pract 2000; 4(Suppl 1)S53–61
   PubMedGoogle Scholar
• Hellewell JSE, Kalali AH, Langham SJ, et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999; 3: 105–13
   PubMedGoogle Scholar
• Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1: 783–801
   PubMedGoogle Scholar
• Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr Res 2002; 53: 239–48
   PubMed Web of Science ®Google Scholar
• Arvanitis, LA, Miller, BG, and the Seroquel Trial 13 study group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–46.
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D, et al. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001; 23: 1839–54
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549–57
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158–69
   PubMed Web of Science ®Google Scholar
• Chue, P, Abouelnasr, W, Escobedo, S, Schweikert, C, Gendron, A. A Canadian multicentre patient satisfaction study with oral long-term quetiapine treatment. Poster presented at the Canadian Psychiatric Association, Banff, Alberta, Canada, 31 October–3 November, 2002.
   Google Scholar
• De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003; 7: 59–66
   PubMed Web of Science ®Google Scholar
• Larmo I, de Nayer A, Windhager E, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum Psychopharmacol Clin Exp 2005; 20: 573–81
   PubMed Web of Science ®Google Scholar
• Guy, W. CGI Clinical Global Impressions. Assessment manual for psychopharmacology – Revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. p. 217–22.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247–51
   PubMed Web of Science ®Google Scholar
• Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–91
   PubMed Web of Science ®Google Scholar
• Larmo, I, Jones, AM, Whiteford, JL, Altman, C. Switching to quetiapine reduces EPS in patients with schizophrenia. Poster presented at the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Montreal, Canada, 23–27, June, 2002.
   Google Scholar
• Larmo, I, Altman, C, Jones, AM, Whiteford, JL. Switching to quetiapine improves drug tolerability in patients with schizophrenia with intolerance or inadequate response to previous therapy. Poster presented at the 15th European College of Neuropsychopharmacology Congress, Barcelona, Spain, 5–9, October, 2002.
   Google Scholar
• Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47–57
   PubMedGoogle Scholar
• Möller H-J, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology (Berlin) 1997; 132: 396–401
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 2003; 166: 391–9
   PubMed Web of Science ®Google Scholar
• Gillain, B, Van Peborgh, P, De Bruecker, G, Peuskens, J. Seroquel™ clinical use in real-life environment – the SECURE study. Poster presented at the 15th European College of Neuropsychopharmacology Congress, Barcelona, Spain, 5–9, October, 2002.
   Google Scholar
• Bovio, H, Jimenez, J, Herranz, S, , et al. Switching to quetiapine in schizophrenic patients with antipsychotic-induced extrapyramidal symptoms. Poster presented at 15th European College of Neuropsychopharmacology Congress, Barcelona, Spain, 5–9, October, 2002.
   Google Scholar
• Cook PE, Goldberg JO, Van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002; 47: 870–4
   PubMed Web of Science ®Google Scholar
• Lee CT, Conde BJ, Mazlan M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002; 63: 569–76
   PubMed Web of Science ®Google Scholar
• Hellewell JSE, Cantillon M. Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol 1998; 8(Suppl)S248(abstr)
   Google Scholar